Skip to main content

Advertisement

SpringerLink
Log in

Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy

  • Pancreas
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Purpose

To identify common and unique pre-treatment prognostic factors in patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC), treated with chemotherapy (CTx) or concurrent chemoradiotherapy (CRT).

Methods

We enrolled 215 patients with BR/LA PDAC, who were treated with either CTx (n = 82) or CRT (n = 133) as a first-line treatment between 2013 and 2016. Clinical data and CT imaging findings for predicting overall survival (OS) and progression-free survival (PFS) were analyzed using Cox regression analysis.

Results

Carbohydrate antigen (CA) 19-9 > 1000 U/mL (hazard ratio [HR] 1.91; p = 0.001) and non-homogeneous enhancement (HR 1.95; p < 0.001) were associated with shorter OS in all study populations. There was no significant difference in median OS (15.3 vs 16.8 months, p = 0.297) and PFS (10.0 vs 11.7 months, p = 0.321) between the CTx and CRT groups. Non-homogeneous enhancement (HR 2.04; p = 0.006) and presence of positive lymph node on CT (HR 2.38; p = 0.036) were associated with poor OS in the CTx group, while CA 19-9 > 1000 U/mL (HR 2.38; p = 0.001) and non-homogeneous enhancement (HR 1.73; p = 0.006) were independent predictors for poor OS in the CRT group.

Conclusion

Enhancement pattern on CT was a common prognostic factor for patients with PDAC treated with either CTx or CRT. Presence of positive lymph nodes on CT was a poor prognostic factor for the CTx group only, whereas CA 19-9 > 1000 U/mL was a poor prognostic factor for the CRT group only.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Raufi AG, Manji GA, Chabot JA, Bates SE (2019) Neoadjuvant Treatment for Pancreatic Cancer. Semin Oncol 46(1):19-27. https://doi.org/10.1053/j.seminoncol.2018.12.002

    Article  CAS  PubMed  Google Scholar 

  2. Al-Hawary MM, Francis IR, Chari ST et al (2014) Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology 270(1):248-260. https://doi.org/10.1148/radiol.13131184

    Article  PubMed  Google Scholar 

  3. (2019) NCCN Guidelines for Patients; Pancreatic Cancer, 2019. https://www.nccn.org/patients/guidelines/pancreatic/index.html

  4. Ducreux M, Cuhna AS, Caramella C et al (2015) Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26 Suppl 5:v56-68. https://doi.org/10.1093/annonc/mdv295

    Article  PubMed  Google Scholar 

  5. Khorana AA, Mangu PB, Berlin J et al (2016) Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34(21):2541-2556. https://doi.org/10.1200/JCO.2016.67.5553

    Article  PubMed  Google Scholar 

  6. Balaban EP, Mangu PB, Khorana AA et al (2016) Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34(22):2654-2668. https://doi.org/10.1200/JCO.2016.67.5561

    Article  PubMed  Google Scholar 

  7. Versteijne E, Vogel JA, Besselink MG et al (2018) Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg 105(8):946-958. https://doi.org/10.1002/bjs.10870

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Suker M, Beumer BR, Sadot E et al (2016) FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17(6):801-810. https://doi.org/10.1016/S1470-2045(16)00172-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Tienhoven GV, Versteijne E, Suker M et al (2018) Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. Journal of Clinical Oncology 36(18_suppl):LBA4002-LBA4002. https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA4002

  10. Sherman WH, Chu K, Chabot J et al (2015) Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma. Cancer 121(5):673-680. https://doi.org/10.1002/cncr.29112

    Article  CAS  PubMed  Google Scholar 

  11. Jang JY, Han Y, Lee H et al (2018) Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Ann Surg 268(2):215-222. https://doi.org/10.1097/SLA.0000000000002705

    Article  PubMed  Google Scholar 

  12. Ng IW, Soon YY, Chen D, Tey JCS (2018) Chemoradiotherapy versus chemotherapy for locally advanced unresectable pancreatic cancer: A systematic review and meta-analysis. Asia Pac J Clin Oncol 14(6):392-401. https://doi.org/10.1111/ajco.12996

    Article  PubMed  Google Scholar 

  13. Ambe C, Fulp W, Springett G, Hoffe S, Mahipal A (2015) A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. J Gastrointest Cancer 46(3):284-290. https://doi.org/10.1007/s12029-015-9734-z

    Article  CAS  PubMed  Google Scholar 

  14. Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, Neoptolemos JP, Ghaneh P (2007) Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96(8):1183-1190. https://doi.org/10.1038/sj.bjc.6603719

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shi S, Yu X (2019) Selecting chemotherapy for pancreatic cancer: Far away or so close? Semin Oncol 46(1):39-47. https://doi.org/10.1053/j.seminoncol.2018.12.004Shi S, Yu X (2019) Selecting chemotherapy for pancreatic cancer: Far away or so close? Semin Oncol 46(1):39-47. https://doi.org/10.1053/j.seminoncol.2018.12.004

    Article  CAS  PubMed  Google Scholar 

  16. Park J, Cho IK, Lee J-C, Lee J, Kim YH, Kim J, Hwang J-H (2019) Enhancements in pancreatic protocol CT as a prognostic indicator in pancreatic cancer. Journal of Clinical Oncology 37(4_suppl):216-216. https://doi.org/10.1200/JCO.2019.37.4_suppl.216

  17. Lee S, Kim SH, Park HK, Jang KT, Hwang JA, Kim S (2018) Pancreatic Ductal Adenocarcinoma: Rim Enhancement at MR Imaging Predicts Prognosis after Curative Resection. Radiology 288(2):456-466. https://doi.org/10.1148/radiol.2018172331

    Article  PubMed  Google Scholar 

  18. Kamarajah SK, Burns WR, Frankel TL, Cho CS, Nathan H (2017) Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis. Ann Surg Oncol 24(7):2023-2030. https://doi.org/10.1245/s10434-017-5810-x

  19. Edge SB, Edge SB, American Joint Committee on C (2017) AJCC cancer staging manual 8th ed. Springer., New York

    Google Scholar 

  20. Hattori Y, Gabata T, Zen Y, Mochizuki K, Kitagawa H, Matsui O (2010) Poorly enhanced areas of pancreatic adenocarcinomas on late-phase dynamic computed tomography: comparison with pathological findings. Pancreas 39(8):1263-1270. https://doi.org/10.1097/MPA.0b013e3181dbc583

    Article  PubMed  Google Scholar 

  21. Park MS, Klotz E, Kim MJ, Song SY, Park SW, Cha SW, Lim JS, Seong J, Chung JB, Kim KW (2009) Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology 250(1):110-117. https://doi.org/10.1148/radiol.2493080226

    Article  PubMed  Google Scholar 

  22. Blouhos K, Boulas KA, Tsalis K, Hatzigeorgiadis A (2015) The isoattenuating pancreatic adenocarcinoma: Review of the literature and critical analysis. Surg Oncol 24(4):322-328. https://doi.org/10.1016/j.suronc.2015.09.006

    Article  CAS  PubMed  Google Scholar 

  23. Verbeke C (2016) Morphological heterogeneity in ductal adenocarcinoma of the pancreas - Does it matter? Pancreatology 16(3):295-301. https://doi.org/10.1016/j.pan.2016.02.004

    Article  PubMed  Google Scholar 

  24. Xue P, Zhu L, Wan Z, Huang W, Li N, Chen D, Hu J, Yang H, Wang L (2015) A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. J Cancer Res Clin Oncol 141(9):1653-1660. https://doi.org/10.1007/s00432-015-1953-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Haas M, Heinemann V, Kullmann F, Laubender RP, Klose C, Bruns CJ, Holdenrieder S, Modest DP, Schulz C, Boeck S (2013) Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol 139(4):681-689. https://doi.org/10.1007/s00432-012-1371-3

    Article  CAS  PubMed  Google Scholar 

  26. Mayahara H, Ito Y, Morizane C, Ueno H, Okusaka T, Kondo S, Murakami N, Morota M, Sumi M, Itami J (2012) Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis. BMC Cancer 12:609. https://doi.org/10.1186/1471-2407-12-609

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Jagric T, Potrc S, Mis K, Plankl M, Mars T (2016) CA19-9 serum levels predict micrometastases in patients with gastric cancer. Radiol Oncol 50(2):204-211. https://doi.org/10.1515/raon-2015-0025

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Maithel SK, Maloney S, Winston C, Gonen M, D’Angelica MI, Dematteo RP, Jarnagin WR, Brennan MF, Allen PJ (2008) Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 15(12):3512-3520. https://doi.org/10.1245/s10434-008-0134-5

    Article  PubMed  Google Scholar 

  29. Portuondo JI, Massarweh NN, Zhang Q, Chai CY, Tran Cao HS (2019) Nodal downstaging as a treatment goal for node-positive pancreatic cancer. Surgery 165(6):1144-1150. https://doi.org/10.1016/j.surg.2018.12.009

    Article  PubMed  Google Scholar 

  30. Sorensen JB, Klee M, Palshof T, Hansen HH (1993) Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67(4):773-775. https://doi.org/10.1038/bjc.1993.140

  31. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7(4):e1000267. https://doi.org/10.1371/journal.pmed.1000267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

None.

Author information

Author notes

  1. Seung-seob Kim and Sunyoung Lee contributed equally to this work as primary authors.

Authors and Affiliations

  1. Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea

    Seung-seob Kim, Sunyoung Lee & Mi-Suk Park

  2. Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

    Hee Seung Lee & Seungmin Bang

Authors
  1. Seung-seob Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sunyoung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hee Seung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seungmin Bang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mi-Suk Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mi-Suk Park.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest related to this manuscript.

Ethics approval

Our institutional review board approved the study (IRB number: 4-2019-0656); requirement for written informed consent for this retrospective study was waived.

Consent to participate

Our institutional review board approved the study (IRB number: 4-2019-0656); requirement for written informed consent for this retrospective study was waived.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 15 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, Ss., Lee, S., Lee, H.S. et al. Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy. Abdom Radiol 46, 655–666 (2021). https://doi.org/10.1007/s00261-020-02661-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-020-02661-w

Keywords

Search

Navigation